SOURCE: Eventide Gilead Fund

Eventide Gilead Fund

December 18, 2012 09:00 ET

Eventide Gilead Fund Ranked #1 Midcap Growth Fund by Lipper and the Wall Street Journal for the One-Year Period Ending November 30, 2012

BOSTON, MA--(Marketwire - Dec 18, 2012) - The Eventide Gilead Fund (NASDAQ: ETGLX), a mutual fund practicing values-based investing, was named ranked #1 in the Midcap Growth equity category, out of 391 funds, for trailing one-year performance by Lipper and the Wall Street Journal. During this period, the Fund generated a return of 19.52% compared with the Russell Mid-Cap Growth Index return of 12.06%, an out-performance of 7.46%.

The Fund was also named as a "Category King" by the Wall Street Journal for the year-to-date (YTD) period ending November 30, 2012, ranking #8 out of 392 Midcap Growth funds. This marked the third time in 2012 the Gilead Fund has been named Category King by the Wall Street Journal, in recognition of ranking in the top ten funds in its category for performance. This is the ninth Category King award the Fund has garnered since inception.

The following table highlights the Fund's performance over the past four years:

As of 9/30/2012   YTD return   1 year return   3 year annualized return   Since inception (7/08/2008) annualized return
Eventide Gilead Fund*   13.35%   34.45%   13.40%   10.69%
S&P 500 Total Return Index   16.44%   30.20%   14.07%   5.27%
Russell Mid-Cap Growth Total Return Index   13.88%   26.69%   16.54%   6.29%

The Eventide Gilead Fund is managed by Eventide Asset Management, LLC, a Boston-based investment advisory firm that is committed to investing in companies that excel at creating value for customers, employees, and society. The Fund was launched on July 8, 2008.

Expenses ratios: Gross Expenses 2.05%; Net Expenses 1.64%. The advisor has agreed to maintain the Fund's total annual operating expenses at 1.64% until at least October 31, 2013. Three-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor's shares, when redeemed, may be worth more or less than their original cost. Please review the fund's prospectus for more information regarding the fund's fees and expenses. Performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).

Lipper Ratings and Lipper Classifications do not constitute and are not intended to constitute investment advice. As a result, you should not make an investment decision on the basis of this information. Rather, you should use Lipper Ratings and Lipper Classifications for informational purposes only.

The S&P 500 is an index created by Standard & Poor's Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. Neither index is an investment product available for purchase.

Mutual Funds involve risk including the possible loss of principal. The fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Fund's ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The fund can have risk associated with a higher portfolio turnover which could result in higher transactional costs.

An investor should consider the Fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Gilead Fund can be found in the Fund's prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771-EVEN (3836). You can also obtain a prospectus at The Eventide Gilead Fund is distributed by Northern Lights Distributors, LLC, which is not affiliated with Eventide Asset Management, LLC.

Contact Information

  • Fund Contact:
    Robin John
    877-771-EVEN (3836), x55


Keyword Cloud

View Website